The weight-loss drug boom has dominated headlines for the last two years — but underneath the hype lies a major flaw in the ...

Linda Yaccarino, CEO of Elon Musk-owned social platform X, said on Wednesday she would step down from the top role in a ...

NVO submits higher-dose Wegovy to EMA, aiming for greater weight loss and stronger defense against rivals in the obesity ...

Touro University Nevada is asking for volunteers to take part in a study on the long-term effects of injectable weight-loss or diabetic medication.

A “click-to-cancel” rule, which would have required businesses to make it easy for consumers to cancel unwanted subscriptions ...

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a ...

S&P 500, Microsoft Corporation, JPMorgan Chase & Co, Eli Lilly and Company. Read 's Market Analysis on Investing.com ...

Ireland has long been a global pharmaceutical powerhouse, hosting more than 90 pharmaceutical companies and employing around ...

The high dose of Wegovy is one part of Novo Nordisk's plan to defend its obesity business, along with a major ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging.

CVS is set to drop Zepbound as a medicine, but will continue to carry other popular weight loss drugs instead.